Navigation Links
Circadian Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid Tumors
Date:10/31/2011

Avastin®, an antibody that blocks the activity of VEGF-A, clinically validated anti-angiogenic drugs as an effective means of inhibiting solid tumour growth. By blocking the interaction of VEGF-A with its receptors, primarily VEGFR-2, the multi-billion dollar cancer therapeutic slows tumour growth by inhibiting blood vessel recruitment into the tumour, effectively starving tumours of essential nutrients and oxygen required for growth. However after a short period of time tumors can begin to grow again in the presence of Avastin® . Avastin® is approved by the US FDA in the following indications: metastatic colorectal cancer, non-squamous-cell lung cancer, metastatic breast cancer, glioblastoma, and metastatic renal cell carcinoma.

The angiogenic receptor VEGFR-2 can also be stimulated by VEGF-C and hence an inhibitor such as VGX-100, a key therapeutic in Circadian's portfolio, can produce greater blockade of this receptor pathway. As such, VGX-100 has the potential to block blood vessel growth in tumours which grow in the presence of Avastin® therapy and hence may completely shut down angiogenesis (the growth of blood vessels) mediated by VEGFR-2.

VEGF-C along with the molecule VEGF-D are also the only known proteins to bind and activate VEGFR-3 which drives lymphatic vessel and tumour-associated blood vessel growth. Inhibitors of VEGF-C thus have therapeutic potential to inhibit not only primary tumour growth through their anti-angiogenic activities, but to also inhibit tumour spread or metastasis via the lymphatic vessels - a mechanism of tumour dissemination that is often the deadliest aspect of many tumour types and a mechanism that is not effectively blocked by anti-VEGF-A or anti-VEGFR-2 therapeutics.

Inherent risks of Investment in Biotechnology Companies There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is desi
'/>"/>

SOURCE Circadian Technologies Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Circadian Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid Tumors
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Cyberonics Receives FDA Approval for Expansion of MRI Use With VNS Therapy® Systems
4. Mylan Receives Approval for Generic Version of MS Contin® Tablets
5. SAFC Verona HPAPI Manufacturing Facility Receives SafeBridge Certification
6. INNOPHARMA Receives FDA Approval of Generic Olanzapine Injection
7. Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System
8. Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial
9. Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China
10. Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets
11. Institute of Health Sciences Receives ABHES Institutional Accreditation for Long Distance Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- UBM Medica US today announced the launch of ... information resource for neurologists and other healthcare providers to ... neurological disorders . The prevalence of ... access to dedicated information for healthcare providers who treat ... , 1 in 6 people are affected ...
(Date:7/23/2014)... , July 23, 2014 Research ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & by ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is segmented into three major segments, namely, holter monitor, ... market was valued at $3,683 million in 2013 and ...
(Date:7/23/2014)... 23, 2014 /PRNewswire-iReach/ -- The Centers for Medicare & ... Innovation Network-Quality Improvement Organization (QIN-QIO) contract to a partnership ... Effective August 1, WVMI will launch Quality Insights ... , Pennsylvania , Delaware ... Louisiana.  The Network will engage providers and the community ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
... 20, 2012   Sysmex America, Inc., a global leader ... today announced its 200th placement of Sysmex WAM ... Laboratory.  Sysmex WAM is now connecting nearly 600 sites ... U.S. and Canada. Sysmex WAM plays a key role ...
... Assured Pharmacy (Pinksheets: APHY), a leading specialty pharmacy group ... present at Anda,s 2012 Supply Chain Symposium on Thursday, ... in Palm Beach Gardens, Florida.  Assured Pharmacy has been ... dispensing controlled substances at pharmacies.   Anda ...
Cached Medicine Technology:Sysmex America Achieves Clinical Laboratory Connectivity Milestone 2Assured Pharmacy to Present at Anda's 2012 Supply Chain Symposium 2Assured Pharmacy to Present at Anda's 2012 Supply Chain Symposium 3
(Date:7/23/2014)... July 24, 2014 The routine ... UPMC greatly increases the likelihood of performing the ... and cancer, report researchers from the University of ... , The test, available at the UPMC/UPCI Multidisciplinary ... the chances of patients getting the correct initial ...
(Date:7/23/2014)... 23, 2014 Men and women who ... for life insurance based on national averages. The Quotes ... rates search to its comprehensive tool this year to ... . , Providers that are now underwriting plans ... reviewed in one or two clicks. The intelligent platform ...
(Date:7/23/2014)... Sellafield or Dounreay since the 1990s are not at ... published in the British Journal of Cancer ... Group at the University of Oxford and from Newcastle ... those who were under 25 and living near Sellafield ... cancer incidence from 1991-2006 between those living near these ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 A new ... a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally ... cancers throughout a woman’s body, Bernstein Liebhard LLP reports. ... the Journal of the American Medical Association, looked at ... morcellator at 500 U.S. hospitals from 2006 to 2012. ...
(Date:7/23/2014)... PA) Asking patients if a suspicious skin lesion ... the spot is likely to be cancerous, according to ... of the Department of Dermatology at Temple University School ... JAMA Dermatology on July 23, 2014, found that ... accompanied by itching, while 28.2 percent involve pain. Non-melanoma ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
... A new type of diagnostic imaging - which can ... cancerous - could be used to prevent unnecessary surgery ... A study by Belgian researchers, which will be ... Society,s Annual Congress in Amsterdam, found that the new ...
... in moderate quantities can reduce the risk of asthma, according ... today (25 September 2011) at the European Respiratory Society,s Annual ... a week could reduce the risk of developing the condition. ... of 12 and 41 yrs of age. All participants completed ...
... A major UK trial has produced firm evidence that ... with early breast cancer significantly reduces the risk of ... The treatment, known as synchronous chemoradiation, has minimal adverse ... of life. Findings from the SEquencing of ...
... of the care of patients with rectal cancer have ... chemotherapy and radiotherapy between European countries. The European ... the European CanCer Organisation compared the treatment ... Netherlands who were diagnosed with rectal cancer between 2008 ...
... for patients with bone metastases from advanced prostate cancer ... III study of an alpha-pharmaceutical in these patients has ... research reported today (Saturday) at the 2011 European Multidisciplinary ... Parker, Consultant Clinical Oncologist at the Royal Marsden Hospital, ...
... Sept. 23 (HealthDay News) -- People,s bodies build up vitamin ... black men who live in areas of the United States ... deficiency than whites who live in the same places. ... recommendations need to change. "This study shows that across-the-board vitamin ...
Cached Medicine News:Health News:New diagnostic imaging for lung cancer could prevent unnecessary surgery 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 3Health News:Treatment of rectal cancer varies enormously between different European countries 2Health News:Treatment of rectal cancer varies enormously between different European countries 3Health News:First Phase III trial of an alpha-pharmaceutical 2Health News:First Phase III trial of an alpha-pharmaceutical 3Health News:Many Black Men in Cold Climates Lack Vitamin D 2
Operating microscope with motorized zoom and variable focus up to 405 mm....
... Opmi Vario/NC33 system microscope provides surgeons with ... These microscopes are ideal for many minimally ... Ergonomically designed at every point of contact. ... in a surgical microscope allows intuitive user ...
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Toothed pituitary rongeur. Straight....
Medicine Products: